(19)
(11) EP 3 650 019 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
11.10.2023 Bulletin 2023/41

(45) Mention of the grant of the patent:
06.09.2023 Bulletin 2023/36

(21) Application number: 19214674.4

(22) Date of filing: 27.05.2015
(27) Previously filed application:
 27.05.2015 PCT/EP2015/061765
(51) International Patent Classification (IPC): 
A61K 31/138(2006.01)
A61K 31/58(2006.01)
A61P 11/00(2006.01)
 A61K 31/439(2006.01)
A61P 11/06(2006.01)
A61K 9/00(2006.01)
(52) Cooperative Patent Classification (CPC):
A61K 31/138; A61K 31/439; A61K 31/58; A61P 11/00; A61P 11/06; A61P 43/00; A61K 9/0075
 
C-Sets:
  1. A61K 31/58, A61K 2300/00;
  2. A61K 31/439, A61K 2300/00;
  3. A61K 31/138, A61K 2300/00;

(54)

FLUTICASONE FUROATE IN THE TREATMENT OF COPD

FLUTICASONFUROAT BEI DER BEHANDLUNG VON COPD

FUROATE DE FLUTICASONE UTILISÉ DANS LE TRAITEMENT DE LA BPCO

(84) Designated Contracting States:
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated Extension States:
BA ME

(30) Priority: 28.05.2014 US 201462003764 P
29.05.2014 US 201462004304 P
27.08.2014 US 201462042506 P

(43) Date of publication of application:
13.05.2020 Bulletin 2020/20

(60) Divisional application:
23191900.2 / 4252742

(62) Application number of the earlier application in accordance with Art. 76 EPC:
15726106.6 / 3148521

(73) Proprietor: GlaxoSmithKline Intellectual Property Development Limited
Stevenage SG1 2NY (GB)

(72) Inventors:
  • BARNES, Neil Christopher
    Uxbridge, Middlesex UB7 8JJ (GB)
  • PASCOE, Steven John
    Research Triangle Park, North Carolina 27709 (US)

(74) Representative: Fowler, Gavin James 
GlaxoSmithKline Global Patents (CN925.1) 980 Great West Road
Brentford, Middlesex TW8 9GS
Brentford, Middlesex TW8 9GS (GB)


(56) References cited: : 
WO-A1-2011/067212
   
  • MONA BAFADHEL ET AL: "Blood Eosinophils to Direct Corticosteroid Treatment of Exacerbations of Chronic Obstructive Pulmonary Disease", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 186, no. 1, 1 July 2012 (2012-07-01), pages 48-55, XP055204840, ISSN: 1073-449X, DOI: 10.1164/rccm.201108-1553OC
  • PASCOE STEVEN ET AL: "Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials.", THE LANCET. RESPIRATORY MEDICINE JUN 2015, vol. 3, no. 6, 13 April 2015 (2015-04-13), pages 435-442, XP008177095, ISSN: 2213-2619
  • NEIL C. BARNES ET AL: "Blood eosinophils as a marker of response to inhaled corticosteroids in COPD", EUROPEAN RESPIRATORY JOURNAL, vol. 47, no. 5, 25 February 2016 (2016-02-25), pages 1374-1382, XP055522832, GB ISSN: 0903-1936, DOI: 10.1183/13993003.01370-2015
   
Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).